SCHEMBL4883072

SCHEMBL4883072

Cc1nsc2nc(CC(C)CNCCC3OCCO3)n(Cc3ccccc3)c(=O)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 2/20 0.41
KIF23 Q02241 1/20 0.41
ALDH1A1 P00352 3/20 0.34
POLB P06746 3/20 0.34
MEN1 O00255 5/20 0.34
KMT2A Q03164 5/20 0.34
LMNA P02545 2/20 0.34
HIF1A Q16665 1/20 0.34
MAPT P10636 4/20 0.33
NPSR1 Q6W5P4 3/20 0.33
KDM4E B2RXH2 2/20 0.33
GAA P10253 1/20 0.33
TP53 P04637 1/20 0.33
PDE1A P54750 1/20 0.33
PDE1B Q01064 1/20 0.33
PDE1C Q14123 1/20 0.33
HTT P42858 3/20 0.32
HPGD P15428 3/20 0.32
ERCC5 P28715 1/20 0.31
FEN1 P39748 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5248653 0.80 KIF11 (0.42) KIF11KIF23
SCHEMBL3892326 0.80 KIF11 (0.49) KIF11KIF23ALDH1A1POLBMEN1
SCHEMBL5232886 0.79 KIF11 (0.51) KIF11KIF23POLBLMNAMAPT
SCHEMBL5233894 0.79 KIF11 (0.47) KIF11KIF23ALDH1A1MEN1KMT2A
SCHEMBL5316070 0.79 KIF11 (0.47) KIF11KIF23ALDH1A1MEN1KMT2A
SCHEMBL3864873 0.79 KIF11 (0.49) KIF11KIF23ALDH1A1MEN1KMT2A
SCHEMBL3869328 0.72 MAPT (0.50) KIF11KIF23POLBMEN1KMT2A
SCHEMBL4063371 0.70 KIF11 (0.77) KIF11KIF23
SCHEMBL3958171 0.69 KIF11 (0.63) KIF11KIF23
SCHEMBL5742317 0.69 KIF11 (0.54) KIF11KIF23ALDH1A1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080153854-A1 NOVEL FUSED HETEROCYCLES AND USES THEREOF ASTRAZENECA AB (SE) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153854-A1 NOVEL FUSED HETEROCYCLES AND USES THEREOF RB1, CDK19, PRMT9 KIF11 1978/4885KIF23 2194/4885ALDH1A1 672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.